APIC is a contract development and manufacturing organization (CDMO) that offers a wide range of services such as synthetic route design, pilot manufacturing, investigational medical manufacturing, and commercial production, by making full use of integrated processes that combine organic synthesis technologies and biotechnologies it has cultivated over many years
Company will invest approximately ¥16 billion to increase production capacity by approximately 70% to ensure a stable supply
The WAVEsystem with the WAVEcontrol 4.0 embedded
The company is focused on therapies such as skinceuticals, gastroenterology, neuropsychiatry, cardiac diabetes care etc.
Advancing to IND-enabling studies with multiple drug candidates
Supports development and commercialization of complex oral drugs using sensitive molecules, including biologicals
Syngene's collaboration with Zoetis started in 2011
Athos will perform multi-omic molecular and genetic analyses using biopsies from archived and de-identified Lahey IBD patient samples
Granite Bio's lead candidate is a novel monoclonal antibody for treatment of autoimmune and certain cancer indications. B
The addition of Sitaglyn and Siglyn to our diabetes portfolio will give patients access to a world-class oral therapy to help people manage their diabetes
Subscribe To Our Newsletter & Stay Updated
